Lila Hope focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships and platform discovery and option deals. In addition, she counsels clients' management, operational and legal teams on day-to-day matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions.  Lila maintains an active practice in cross-border licensing transactions, concluding over 20 transactions involving Asian biotechnology companies between 2015 and 2021.

Download full bio 

Experience

  • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 

  • CardioKinetix Completes $50 Million Financing 

  • Adamas Pharmaceuticals Initial Public Offering 

  • Ascendis Pharma closes $124 million IPO 

  • Nexvet Biopharma Closes Initial Public Offering 

  • View all

Education

  • Duke University School of Law
    JD, magna cum laude, 2002

  • Stanford University
    PHD, Cancer Biology
    1999

  • Oregon Graduate Institute
    MS, 1993


Admissions & Credentials

California

Memberships

  • American Bar Association

Rankings & Accolades

    Chambers USA: Life Sciences - Corporate/Commercial

    Legal 500: Healthcare: Life Sciences